Tags

Type your tag names separated by a space and hit enter

[What scientific and clinical findings will result from the controlled trial "Women's Health Initiative"?].
Bull Mem Acad R Med Belg. 2003; 158(1-2):133-41; discussion 141-5.BM

Abstract

The Women's Health Initiative Study is the first large randomized controlled trial for primary prevention, comparing the beneficial or adverse effects of an oral continuous-combined regimen of conjugated estrogens + medroxyprogesterone acetate, vs placebo in late postmenopausal women. This study brings evidence for an absence of preventive cardiovascular effects of hormone replacement therapy (HRT), shows for the first time a small increase in risk for coronary disease, and confirms a small increased risk for invasive breast cancer from four-five years of treatment on, a reduction of risk of colorectal cancer and osteoporotic fractures, and a moderate increase in other already known cardiovascular risks during HRT, such as venous thromboembolism and stroke. Although this study has inherent limitations and may be criticised, and the observed risks are restricted, it forces the physician to better respect known contra-indications (a.o. vascular) to HRT, to carefully weigh the benefit/risk balance of the patients, shorten HRT administration (4-5 years?), use minimal effective hormone dosages, preferably by non-oral route, and change for new compounds with more selective estrogenic action, which are under development.

Authors

No affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article
Randomized Controlled Trial

Language

fre

PubMed ID

12852099

Citation

Gaspard, U. "[What Scientific and Clinical Findings Will Result From the Controlled Trial "Women's Health Initiative"?]." Bulletin Et Memoires De l'Academie Royale De Medecine De Belgique, vol. 158, no. 1-2, 2003, pp. 133-41; discussion 141-5.
Gaspard U. [What scientific and clinical findings will result from the controlled trial "Women's Health Initiative"?]. Bull Mem Acad R Med Belg. 2003;158(1-2):133-41; discussion 141-5.
Gaspard, U. (2003). [What scientific and clinical findings will result from the controlled trial "Women's Health Initiative"?]. Bulletin Et Memoires De l'Academie Royale De Medecine De Belgique, 158(1-2), 133-41; discussion 141-5.
Gaspard U. [What Scientific and Clinical Findings Will Result From the Controlled Trial "Women's Health Initiative"?]. Bull Mem Acad R Med Belg. 2003;158(1-2):133-41; discussion 141-5. PubMed PMID: 12852099.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [What scientific and clinical findings will result from the controlled trial "Women's Health Initiative"?]. A1 - Gaspard,U, PY - 2003/7/11/pubmed PY - 2003/9/25/medline PY - 2003/7/11/entrez SP - 133-41; discussion 141-5 JF - Bulletin et memoires de l'Academie royale de medecine de Belgique JO - Bull Mem Acad R Med Belg VL - 158 IS - 1-2 N2 - The Women's Health Initiative Study is the first large randomized controlled trial for primary prevention, comparing the beneficial or adverse effects of an oral continuous-combined regimen of conjugated estrogens + medroxyprogesterone acetate, vs placebo in late postmenopausal women. This study brings evidence for an absence of preventive cardiovascular effects of hormone replacement therapy (HRT), shows for the first time a small increase in risk for coronary disease, and confirms a small increased risk for invasive breast cancer from four-five years of treatment on, a reduction of risk of colorectal cancer and osteoporotic fractures, and a moderate increase in other already known cardiovascular risks during HRT, such as venous thromboembolism and stroke. Although this study has inherent limitations and may be criticised, and the observed risks are restricted, it forces the physician to better respect known contra-indications (a.o. vascular) to HRT, to carefully weigh the benefit/risk balance of the patients, shorten HRT administration (4-5 years?), use minimal effective hormone dosages, preferably by non-oral route, and change for new compounds with more selective estrogenic action, which are under development. SN - 0377-8231 UR - https://www.unboundmedicine.com/medline/citation/12852099/[What_scientific_and_clinical_findings_will_result_from_the_controlled_trial_"Women's_Health_Initiative"]_ DB - PRIME DP - Unbound Medicine ER -